Gilead Sciences, Inc. (GILD)
Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices
Gilead Sciences reported good quarterly results and in the last few weeks, the stock rallied higher. Oncology will especially contribute to growth in the years to come, and maybe Gilead Sciences will also be a player in the anti-obesity market. The stock is still trading for a reasonable valuation multiple and in case of a potential recession, pharmaceutical companies are often a good, recession-resilient pick.
Gilead Sciences: Buy This Bargain Before It's Gone
Since my last article, Gilead Sciences, Inc.'s stock price has continued to rise, thanks in part to strong sales of its HIV portfolio and an improved EBIT margin year-over-year. So, sales of the company's HIV franchise amounted to about $4.75 billion in the second quarter, an increase of 9.3% quarter-on-quarter. In addition, on August 14, 2024, the FDA approved Livdelzi in combination with UDCA for the treatment of primary biliary cholangitis.
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
While Gilead's (GILD) performance has been good in the past three months on robust second-quarter results and pipeline progress, we will wait before recommending the stock.
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
Gilead (GILD) wins FDA nod for seladelpar for the treatment of primary biliary cholangitis (PBC) on an accelerated basis.
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit
Gilead Sciences says counterfeit versions of its HIV medications were being sold out of two New York pharmacies. Court documents alleged a twice-convicted medical fraudster wearing a court-ordered GPS ankle monitor was behind the scheme.
US FDA approves Gilead's liver disease drug
The U.S. Food and Drug Administration said on Wednesday it has approved Gilead Sciences' drug for a chronic and potentially fatal liver disease that mostly affects women.
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels
On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of $6.72 billion.
Gilead Posts Solid Revenue in Q2
Revenue of $7.0 billion, up 6% excluding Veklury. Non-GAAP diluted EPS of $2.01.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Gilead Sciences, Inc. (GILD) Q2 2024 Earnings Call Transcript
Gilead Sciences, Inc. (NASDAQ:GILD ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jacquie Ross - Vice President, Investor Relations Daniel O'Day - Chairman and Chief Executive Officer Johanna Mercier - Chief Commercial Officer Merdad Parsey - Chief Medical Officer Andrew Dickinson - Chief Financial Officer Cindy Perettie - Executive Vice President, Kite Conference Call Participants Evan Seigerman - BMO Capital Markets Terence Flynn - Morgan Stanley Daina Graybosch - Leerink Partners Umer Raffat - Evercore ISI Carter Gould - Barclays Michael Yee - Jefferies Brian Abrahams - RBC Capital Markets Chris Schott - JPMorgan Steven Seedhouse - Raymond James Tim Anderson - Wolf Research Salveen Richter - Goldman Sachs Olivia Brayer - Cantor Fitzgerald Operator Good afternoon, everyone, and welcome to Gilead's Second Quarter 2024 Earnings Conference Call. My name is Rebecca, and I'll be your host for today.
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
